Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113572 | 0.88 | MAPK1 (0.36) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL2274062 | 0.86 | KIT (0.34) | MAPK1CNR1ACHECNR2GRIA1 | |
| SCHEMBL3268491 | 0.85 | CASR (0.37) | CNR1ACHECNR2 | |
| SCHEMBL18113578 | 0.84 | L3MBTL1 (0.47) | MAPK1CNR1ACHECNR2 | |
| SCHEMBL12373945 | 0.81 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPI4KAPIK3CG | |
| SCHEMBL27811931 | 0.80 | MEN1 (0.37) | PDE10ACNR1ACHECNR2 | |
| SCHEMBL2280858 | 0.76 | CNR1 (0.35) | PIK3CAMAPK1PDE10ACNR1ACHE | |
| SCHEMBL18113516 | 0.76 | MAPK1 (0.41) | MAPK1GRIA1 | |
| SCHEMBL18113517 | 0.76 | MAPK1 (0.41) | MAPK1GRIA1 | |
| SCHEMBL20395795 | 0.76 | MAPK1 (0.41) | MAPK1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067266-A1 | PYRROLIDINYL-BASED COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-08 | — | — | WO | disclosed |
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| EP-3277690-B1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
| EP-3277690-A1 | SPIROCYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016161160-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268714-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | PIK3CA 620/4885PIK3CD 1620/4885PIK3CB 1344/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | PIK3CA 620/4885PIK3CD 1620/4885PIK3CB 1344/4885 |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | PIK3CA 162/4885PIK3CD 164/4885PIK3CB 194/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | PIK3CA 620/4885PIK3CD 1620/4885PIK3CB 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.